RBC rates Endo at outperform

RBC Capital Markets analyst Ken Trbovich rated Endo Pharmaceuticals Holdings Inc. at outperform, above average risk, on news it acquired all of the outstanding shares of privately held RxKinetix. The company's lead product is RK-0202, an oral rinse formulation for the treatment of oral mucositis, which affects about 400,000 U.S. cancer patients. Endo paid $20 million up front to acquire RxKinetix and could pay up to an additional $95 million to RxKinetix shareholders, according to the analyst. Shares of the Chadds Ford, Pa.-based pharmaceutical company were up 74 cents, or 2.21%, at $34.23. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.